Notably, the phase II TURBO-NSCLC trial demonstrated that combining EGFR TKIs with early stereotactic radiosurgery (SRS) improved time to CNS progression and local control, especially in patients with lesions ≥ 1 cm, though without an OS benefit [16]. Here, EGFR is linked to non-small cell lung carcinoma.